14,060 Shares in Enovis Corporation $ENOV Bought by Dynamic Technology Lab Private Ltd

Key Points

• Dynamic Technology Lab has invested approximately $537,000 in Enovis Corporation, acquiring 14,060 shares in the first quarter, which follows significant stakes added by other institutional investors.
• Several analysts have adjusted their price targets for Enovis, with estimates now ranging from $41.00 to $58.00, while maintaining a consensus rating of "Buy" for the stock.
• Enovis reported a 7.5% year-over-year revenue increase to $564.5 million in its latest quarterly earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.79.

Dynamic Technology Lab Private Ltd bought a new position in Enovis Corporation (NYSE:ENOV - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 14,060 shares of the company's stock, valued at approximately $537,000.

Several other institutional investors have also recently made changes to their positions in the company. California State Teachers Retirement System raised its position in shares of Enovis by 0.7% in the 4th quarter. California State Teachers Retirement System now owns 52,236 shares of the company's stock worth $2,292,000 after acquiring an additional 350 shares in the last quarter. Humankind Investments LLC grew its stake in shares of Enovis by 8.6% in the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company's stock worth $217,000 after buying an additional 452 shares during the last quarter. US Bancorp DE grew its stake in shares of Enovis by 2.5% in the 1st quarter. US Bancorp DE now owns 19,031 shares of the company's stock worth $727,000 after buying an additional 462 shares during the last quarter. Leisure Capital Management grew its stake in shares of Enovis by 2.2% in the 1st quarter. Leisure Capital Management now owns 22,903 shares of the company's stock worth $875,000 after buying an additional 489 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after buying an additional 536 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Insider Transactions at Enovis

In related news, SVP Bradley J. Tandy bought 3,200 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were bought at an average cost of $31.41 per share, with a total value of $100,512.00. Following the acquisition, the senior vice president owned 43,515 shares in the company, valued at $1,366,806.15. This trade represents a 7.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Damien Mcdonald bought 6,457 shares of the firm's stock in a transaction that occurred on Thursday, September 11th. The stock was bought at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the acquisition, the chief executive officer owned 102,753 shares in the company, valued at $3,182,260.41. This trade represents a 6.71% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 12,157 shares of company stock worth $374,760 in the last ninety days. Insiders own 2.70% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Canaccord Genuity Group cut their price target on Enovis from $70.00 to $58.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. UBS Group cut their price target on Enovis from $65.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Wells Fargo & Company cut their price target on Enovis from $48.00 to $41.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Needham & Company LLC cut their price target on Enovis from $57.00 to $49.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Finally, Evercore ISI cut their price target on Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $51.00.

Enovis Stock Performance

Shares of ENOV stock traded up $0.96 on Tuesday, reaching $33.30. The stock had a trading volume of 1,671,716 shares, compared to its average volume of 898,984. The stock has a market cap of $1.90 billion, a P/E ratio of -2.34 and a beta of 1.68. Enovis Corporation has a 1 year low of $25.47 and a 1 year high of $49.83. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25. The company has a 50 day simple moving average of $29.81 and a 200 day simple moving average of $32.64.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.05. The firm had revenue of $564.50 million for the quarter, compared to the consensus estimate of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company's revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the business posted $0.62 EPS. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. Equities research analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.